Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kinesin family member 26A (KIF26A)
- Target
- KIF26A
- Molecular classification
- Kinesin superfamily protein, Motor protein, Microtubule-associated protein
01
Overview
Kinesin family member 26A (KIF26A) is an atypical member of the kinesin superfamily of motor proteins, characterized by microtubule binding capabilities but lacking classical ATPase activity. It plays versatile regulatory roles in cellular processes such as neuronal migration, neuron projection development, cerebral cortex development, and intracellular calcium homeostasis. In disease, KIF26A acts as a negative regulator of GDNF–Ret signaling in the enteric nervous system and modulates cancer cell proliferation and migration in a context-dependent manner. It is also involved in maintaining cytoskeletal dynamics, tissue repair, and possibly regulates nociceptive signaling. Genetic studies implicate KIF26A variants in musculoskeletal injury and certain complex cortical malformations[1][2].
- Other names
- KIF26Akinesin family member 26A
02
Mechanism of action
For hypothetical drugs targeting KIF26A, the mechanism could involve modulation of microtubule binding activity, alteration of GDNF–Ret signaling, or regulation of cell cycle progression, but no drugs are reported
03
Biological functions
Microtubule binding and stabilizationRegulation of cell signaling (e.g., GDNF–Ret pathway)Cell cycle regulation (G0/G1 progression)Neuronal migration and projection developmentIntracellular calcium homeostasisCytoskeletal organizationModulation of neuronal axon morphologyNegative regulation of nociceptive sensationTissue regeneration (wound healing)
04
Disease associations
Cancer (roles in gastric and breast cancer)Neurodevelopmental disorders (e.g., cerebral cortex malformations)Musculoskeletal injury and extracellular matrix integrityEnteric nervous system disease (e.g., megacolon)
05
Safety considerations
Potential disruption of neurodevelopment, enteric nervous system function, or tissue homeostasis if targeted therapeutically.Unknown long-term effects due to broad roles in cell signaling and cytoskeletal organization
Beyond the preview
Go deeper on Kinesin family member 26A (KIF26A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinesin family member 26A (KIF26A).